In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

Researchers found that tirzepatide, a medication primarily used ... which may indicate a new direction for research possibilities. "For those living with obesity or diabetes, the field of weight loss ...

Using tirzepatide and menopause hormone therapy at the ... "This study underscores the urgent need for further research to better understand how obesity medications and menopause hormone therapy work ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being ...

New animal research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide ...

Tirzepatide vs. Semaglutide for Obesity. 2025-07-03. DOI: 10.1056/NEJMdo008040 ... New research findings are summarized in a short video. Video Summary of. Original Article; May 11, 2025; ...

Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...